Recently, we reported the dual inhibition of
cyclooxygenase-2 (COX-2) and
5-lipoxygenase (5-LO) activity by some phenylsulphonyl urenyl
chalcone derivatives. 2,4-dichloro-4'N[N'(4''methylphenylsulphonyl)urenyl]
chalcone (Me-UCH9), was selected in the present study to determine its potential anti-inflammatory and
analgesic effect after
oral administration in several animal models related to the activation of COX-2 and 5-LO pathways. In the
zymosan stimulated mouse air pouch model,
Me-UCH9, reduced in a dose-dependent manner
leukotriene B(4) (LTB(4)) levels in pouch exudates obtained at 4 h, as well as
prostaglandin E(2) (
PGE(2)) generated through COX-2 activation at 24 h.
Tumor necrosis factor alpha (
TNF-alpha) and
myeloperoxidase activity were also strongly inhibited in this model.
Me-UCH9 significantly reduced
granuloma size and vascular index determined in the murine air pouch
granuloma model of angiogenesis. In the
carrageenan-induced paw
edema, this compound inhibited inflammatory response and
pain, as well as
PGE(2) and LTB(4) content in paw edematous fluid.
Analgesic properties were corroborated in the murine
phenyl-p-benzoquinone-induced writhing test. Finally,
Me-UCH9 exerted anti-inflammatory effects in the chronic model of rat adjuvant-induced
arthritis, both inhibiting paw swelling and reducing
PGE(2) content. Our findings confirm that
Me-UCH9 can modulate inflammatory and nociceptive responses in relation to the dual inhibition of COX-2 and 5-LO activities presented by this compound.